Celgene Corp (CELG.O)
Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.
July 25 Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.
* Interim analysis of overall survival, a key secondary endpoint, showed no benefit in revlimid
CORRECTED-BRIEF-Jounce Therapeutics to collaborate with Celgene to develop immuno-oncology therapies
* Jounce Therapeutics says to receive upfront payment of $225 million and $36 million equity investment, up to $2.3 billion in future milestone payments
July 5 U.S. cancer drug company Medivation Inc said on Tuesday it had agreed to provide confidential information to French pharmaceutical company Sanofi SA as part of exploring a sale that would be open to other bidders.
* Celgene announces additional $3 billion share repurchase authorization
* Says scientific collaborations include possible extension of ongoing collaboration with Celgene Corporation Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association
Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,548||+35.00|
|Eisai Co., Ltd (4523.T)||¥6,213||+10.00|
|Johnson & Johnson (JNJ.N)||$124.84||-0.31|
|Novartis AG (NOVN.S)||CHF81.90||-0.60|
|Pfizer Inc. (PFE.N)||$36.82||-0.01|
|Roche Holding Ltd. (ROG.S)||CHF249.30||-1.00|
|Roche Holding Ltd. (RO.S)||CHF250.00||-1.25|
|Merck & Co., Inc. (MRK.N)||$58.55||+0.19|
|Sanofi SA (SASY.PA)||€76.70||+0.13|
|AstraZeneca plc (AZN.L)||4,690.00p||+51.50|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (CELG). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : Wright Reports
Provider : ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.